Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Deffered Revenue: 2020

Historic Non-Current Deffered Revenue for Oncology Institute (TOI) over the last 1 years, with FY2020 value amounting to $6.3 million.

  • Oncology Institute's Non-Current Deffered Revenue changed 0.0% to $6.3 million in Q3 2021 from the same period last year, while for Sep 2021 it was $6.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $6.3 million for FY2020, which is N/A changed from last year.
  • As of FY2020, Oncology Institute's Non-Current Deffered Revenue stood at $6.3 million.
  • Over the past 5 years, Oncology Institute's Non-Current Deffered Revenue peaked at $6.3 million during FY2020, and registered a low of $6.3 million during FY2020.